Sugi Predict

Sugi Predict / Compounds / SCHEMBL4200604

SCHEMBL4200604

SCHEMBL4200604

O=Cc1cccc(OCc2ccccc2F)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.68
▸ RAB9A P51151 2/20 0.68
▸ MAOB P27338 10/20 0.63
▸ MAOA P21397 7/20 0.63
▸ LMNA P02545 2/20 0.60
▸ KDM4E B2RXH2 1/20 0.60
▸ TSHR P16473 1/20 0.60
▸ HTT P42858 1/20 0.60
▸ SPHK2 Q9NRA0 1/20 0.55
▸ TDP1 Q9NUW8 1/20 0.54
▸ EGFR P00533 1/20 0.53
▸ GSK3B P49841 1/20 0.53
▸ CCNB2 O95067 1/20 0.52
▸ CDK1 P06493 1/20 0.52
▸ CDK4 P11802 1/20 0.52
▸ CCNB1 P14635 1/20 0.52
▸ CCND1 P24385 1/20 0.52
▸ CCNB3 Q8WWL7 1/20 0.52
▸ ALDH1A1 P00352 1/20 0.52
▸ PARP15 Q460N3 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2668344 0.88 NPC1 (0.51) NPC1RAB9AMAOBMAOALMNA
SCHEMBL4244280 0.85 PTPN1 (0.56) NPC1RAB9AMAOBTSHRALDH1A1
SCHEMBL31556124 0.85 PTPN1 (0.56) NPC1RAB9AMAOBTSHRALDH1A1
SCHEMBL18001900 0.85 MAOA (0.62) NPC1RAB9AMAOBMAOALMNA
SCHEMBL712032 0.84 MAOB (0.50) NPC1RAB9AMAOBMAOALMNA
SCHEMBL19595052 0.83 MAOB (0.56) NPC1RAB9AMAOBMAOALMNA
SCHEMBL2168244 0.83 TSHR (0.60) NPC1RAB9AMAOBLMNAKDM4E
SCHEMBL18001983 0.82 MAOA (0.59) NPC1RAB9AMAOBMAOALMNA
SCHEMBL8985589 0.82 NPC1 (0.68) NPC1RAB9AMAOBMAOALMNA
SCHEMBL12517230 0.82 CDK4 (0.75) NPC1RAB9AMAOBMAOAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11884673-B2 Modulators of ion channel receptors and uses thereof BIONOMICS LIMITED (AU) 2024-01-30 — — US disclosed
US-20220251099-A1 MODULATORS OF ION CHANNEL RECEPTORS AND USES THEREOF BIONOMICS LTD (AU) 2022-08-11 — — US disclosed
US-11384085-B2 Modulators of ion channel receptors and uses thereof BIONOMICS LIMITED (AU) 2022-07-12 — — US disclosed
US-11384085-B2 Modulators of ion channel receptors and uses thereof BIONOMICS LIMITED (AU) 2022-07-12 — — US disclosed
US-20210230165-A1 MODULATORS OF ION CHANNEL RECEPTORS AND USES THEREOF BIONOMICS LIMITED (AU) 2021-07-29 — — US disclosed
US-20210230165-A1 MODULATORS OF ION CHANNEL RECEPTORS AND USES THEREOF BIONOMICS LIMITED (AU) 2021-07-29 — — US disclosed
EP-3794000-A1 MODULATORS OF ION CHANNEL RECEPTORS AND USES THEREOF Bionomics Limited (AU) 2021-03-24 — — EP disclosed
WO-2019218025-A1 MODULATORS OF ION CHANNEL RECEPTORS AND USES THEREOF BIONOMICS LIMITED (AU) 2019-11-21 — — WO disclosed
WO-2019218025-A1 MODULATORS OF ION CHANNEL RECEPTORS AND USES THEREOF BIONOMICS LIMITED (AU) 2019-11-21 — — WO disclosed
EP-2029524-A1 PROCESS FOR THE PRODUCTION OF 2- [4 - ( 3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPAN AMIDES Newron Pharmaceuticals S.p.A. (IT) 2009-03-04 — — EP disclosed
EP-1687259-B1 CYCLOPENTYL DERIVATES NEWRON PHARM SPA (IT) 2007-08-08 — — EP disclosed
US-20070066688-A1 Cyclopentyl derivatives NEWRON PHARMACEUTICALS S.P.A. (IT) 2007-03-22 — — US disclosed
EP-1687259-A1 CYCLOPENTYL DERIVATES Newron Pharmaceuticals S.p.A. (IT) 2006-08-09 — — EP disclosed
WO-2005054178-A1 CYCLOPENTYL DERIVATIVES NEWRON PHARMACEUTICALS S.P.A. (IT) 2005-06-16 — — WO disclosed
EP-1533295-A1 Cyclopentyl Derivatives Newron Pharmaceuticals S.p.A. (IT) 2005-05-25 — — EP disclosed
EP-1150952-B1 INDOLE DERIVATIVES AND THEIR USE AS MCP-1 RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2004-10-27 — — EP disclosed
US-6737435-B1 ANTIINFLAMMATORY AGENTS; MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) DISEASES ASTRAZENECA AB (SE) 2004-05-18 — — US disclosed
US-20030144339-A1 Indole derivatives as mcp-1 receptor antagonists ASTRAZENECA AB (SE) 2003-07-31 — — US disclosed
EP-1150952-A1 INDOLE DERIVATIVES AND THEIR USE AS MCP-1 RECEPTOR ANTAGONISTS AstraZeneca AB (SE) 2001-11-07 — — EP disclosed
WO-2000046196-A1 INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS ASTRAZENECA AB (SE) 2000-08-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210230165-A1 MODULATORS OF ION CHANNEL RECEPTORS AND USES THEREOF TRPV1, TRPM8, TRPV2 NPC1 1634/4885RAB9A 1974/4885MAOB 2653/4885
US-20030144339-A1 Indole derivatives as mcp-1 receptor antagonists CCR2, CCR1, CCR5 NPC1 1058/4885RAB9A 1599/4885MAOB 1588/4885
US-11384085-B2 Modulators of ion channel receptors and uses thereof TRPV1, TRPM8, TRPV2 NPC1 1634/4885RAB9A 1974/4885MAOB 2653/4885
US-11884673-B2 Modulators of ion channel receptors and uses thereof TRPV1, TRPM8, TRPV2 NPC1 1634/4885RAB9A 1974/4885MAOB 2653/4885
US-20220251099-A1 MODULATORS OF ION CHANNEL RECEPTORS AND USES THEREOF TRPV1, TRPM8, TRPV2 NPC1 1634/4885RAB9A 1974/4885MAOB 2653/4885
US-20070066688-A1 Cyclopentyl derivatives HCN3, RYR2, KCNN3 NPC1 991/4885RAB9A 2079/4885MAOB 1293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.